Sorry, it's another link to a possible new therapy, got to keep positive

[Headache58]

gritdaily.com/alzheimers-br...

[MBAnderson]

A credible article. Because it's an article, we need to see the studies. However, very well worth following.

[jimcaster]

I will never understand why the trial process for something this promising for a disease like Alzheimer’s Disease isn't expedited on some sort of emergency basis like the Covid-19 vaccines were. What do Alzheimer’s patients have to lose?

[Boscoejean in reply to jimcaster]

exactly so in this article they say it was proven in 2019 and you look on clinical trials and there are none in the US so what gives

[Gymsack]

Do not be afraid to bring anything here. You never know what is useful and just because some old guy does not agree with the findings is not reason to not present it.Thanks

[Headache58 in reply to Gymsack]

Thank you

[Gioc]

Very interesting and I quote:

“There are two additional mechanisms that we have seen in our studies with NVG-291 that could be very important in the treatment of Alzheimer’s,” says Dr. Jerry Silver. “First, there is the reduction of inflammation in the immune cells of the brain. Second, there is the promotion of autophagy, which is a cellular cleaning mechanism that is necessary for healthy neurons “.

Two very familiar things here on HUCP:

“ First, there is the reduction of inflammation in the immune cells of the brain. Second, there is the promotion of autophagy, “👍👍👍

[WinnieThePoo]

Thanks. One of the most exciting developments I've seen, and although nobody seems to have linked it with PD yet, a repaired neuron is a repaired neuron

Jim. Looks like this one is going through pretty fast. The issue with Slow PD research fast covid vaccine is the nature of the remedy. In effect, a covid vaccine is a symptomatic therapy, not a disease modifier. It either does or does not prevent infection. And you can test that in a matter of weeks.

The interesting PD therapies are in the main disease modifiers. It takes probably at least 2 years to demonstrate that, and most of the drugs have shown only marginal success at best.

This is going to repair neurons. If it works, that should be demonstrated quickly

[jimcaster in reply to WinnieThePoo]

That makes sense although I would still hope they could expedite things. Obviously, we are all a little biased, but I just don't get a sense of urgency for addressing slowly progressive neurodegenerative diseases. If people actually dropped dead within weeks of an AD or PD diagnosis, I think we'd be way ahead of where we are now...but I admit that my sense of urgency/frustration is a bit tainted.

[kevowpd in reply to jimcaster]

C19 was threatening to crater every economy and overwhelm many if not every hospital system. You cant operate a civilised society if people cant work or car accident victims cant get to the ER in time.

PD and ALZ might be squeeky enough wheels one day to attract more attention but its tomorrow's problem and governments dont really care about those when most voters dont.

[Headache58 in reply to kevowpd]

To true, but as pointed out in one article, the financial rewards that would come to the first big, or little, pharma company that can deliver a cure or even something that stops progression would be vast. Why are they not pulling out all the stops

[kevowpd in reply to Headache58]

Good question. I believe its because public equity markets value dividends next quarter, not in 20 years' time. There's a lot of investment at the moment but much of it seems to be coming from borderline venture capitalists. Long shots with big potential payouts. Not really feasible for a listed biz to bet the farm on a cure for PD

[Boscoejean]

the first time I searched this on clinical trials nothing came up- the second time it came up with a clinical trial for brain injury but nothing about alzheimersclinicaltrials.gov/ct2/show...

[Canddy in reply to Boscoejean]

It has to go through a Phase 1 trial (typically in healthy adults) to prove that various doses are safe. The study you have linked is the Phase 1 trial which was supposed to be completed in May 2022. I don't see any results on clinicaltrials.gov nor on the company's website -

nervgen.com/

It takes a little time to crunch the data, but I would think if the Phase I trial showed that the drug was safe it should be announced by end of July 2022. If Phase 1 pans out, then the company plans to move into Phase 1b/2 trials in Q4 2022. In Phase (1b/2) the drug is given to actual patients (in this case people with Alzheimer's disease) in order to determine safety, efficacy, metabolism, pharmacokinetic properties and clinical pharmacology of the drug. According to the company's website the results from Phase 1b/2 if launched will not be available until 2024.

[Boscoejean in reply to Canddy]

so since the guy who developed it seems to be in Ohio why then the trial in Australia

[Canddy in reply to Boscoejean]

Maybe the Phase I clinic was available during the time period that the company wanted to run the study. Some academic centers have Phase I units, but many are stand-alone entities scattered across different countries (including the US). There is a Phase I unit located in Lincoln NE for example that largely depends on the college age population for its patient pool (healthy volunteers).

Or perhaps there were regulatory concerns in the US - hard to say BUT if the data was positive -i.e., the drug was safe - we should hear about it before the end of (US) summer.

[Boscoejean]

clinical trial location is Australia and it appears female only participants